Aurinia Pharmaceuticals (AUPH) Other Accumulated Expenses (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 8 years of Other Accumulated Expenses data on file, last reported at $2.5 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 48.79% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 48.79% YoY) and the FY2025 annual result came in at $2.5 million, up 61.99% from the prior year.
• Other Accumulated Expenses rose to $2.5 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.6 million in Q3 2023 to a low of $502000.0 in Q1 2022.
• A 5-year average of $1.8 million and a median of $2.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 88.79% — and 2023, when it soared 294.22%.
• Tracing AUPH's Other Accumulated Expenses over 5 years: stood at $2.0 million in 2022, then climbed by 17.46% to $2.4 million in 2023, then tumbled by 35.89% to $1.5 million in 2024, then soared by 61.99% to $2.5 million in 2025, then gained by 1.69% to $2.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $2.5 million (Q1 2026), $2.5 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.